Alpha cell function in health and disease: influence of glucagon-like peptide-1. (Q34560507)

3 August 2017

1 reference

title

Alpha cell function in health and disease: influence of glucagon-like peptide-1. (English)

1 reference

3 August 2017

1 reference

3

Ahrén B

1 reference

3 August 2017

Dunning BE

1

1 reference

3 August 2017

Foley JE

series ordinal

2

1 reference

3 August 2017

publication date

13 August 2005

1 reference

3 August 2017

1 reference

3 August 2017

volume

48

1 reference

3 August 2017

issue

9

1 reference

3 August 2017

page(s)

1700-1713

1 reference

The Structure-Function Relationship of GLP-1 Related Peptides in the Endocrine Function of the Canine Pancreas

3 August 2017

cites work

1 reference

12 December 2020

Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells

1 reference

12 December 2020

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

1 reference

12 December 2020

Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes

1 reference

12 December 2020

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

1 reference

12 December 2020

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.

1 reference

12 December 2020

Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes

1 reference

12 December 2020

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

1 reference

12 December 2020

Metabolic and hormonal responses to exogenous hyperthermia in man.

1 reference

12 December 2020

Hyperglucagonemia and alpha-adrenergic receptor in acute hypoxia

1 reference

12 December 2020

Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone

1 reference

12 December 2020

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

1 reference

12 December 2020

Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations

1 reference

12 December 2020

Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans

1 reference

12 December 2020

Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia

1 reference

12 December 2020

Suppression of synthesis and release of glucagon by glucagon-like peptide-1 (7-36 amide) without affect on mRNA level in isolated rat islets

1 reference

12 December 2020

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

1 reference

12 December 2020

Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study.

1 reference

12 December 2020

Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon

1 reference

12 December 2020

Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal n

1 reference

12 December 2020

Incretins, insulin secretion and Type 2 diabetes mellitus

1 reference

12 December 2020

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

1 reference

12 December 2020

Differential effect of isoproterenol on acute glucagon and insulin release in man

1 reference

12 December 2020

Immunoassay of endogenous plasma insulin in man

1 reference

12 December 2020

Actions of neurohypophysial peptides on pancreatic hormone release

1 reference

12 December 2020

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

1 reference

12 December 2020

Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans.

1 reference

12 December 2020

Effect of beta-hydroxybutyrate and acetoacetate on insulin and glucagon secretion from perfused rat pancreas

1 reference

12 December 2020

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

1 reference

12 December 2020

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions

1 reference

12 December 2020

Glucagon antibodies and an immunoassay for glucagon

1 reference

12 December 2020

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

1 reference

12 December 2020

Glucagon-stimulating activity of 20 amino acids in dogs

1 reference

12 December 2020

The mechanism of vagal nerve stimulation of glucagon and insulin secretion in the dog

1 reference

12 December 2020

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

1 reference

12 December 2020

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons

1 reference

12 December 2020

Glucagon immunoreactivity in plasma from normal and dystrophic mice

1 reference

12 December 2020

Relationship of islet function to insulin action in human obesity

1 reference

12 December 2020

Normalization of fasting hyperglucagonemia and excessive glucagon responses to intravenous arginine in human diabetes mellitus by prolonged infusion of insulin

1 reference

12 December 2020

Counterregulation in Type 2 (non-insulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses, up to ten years after diagnosis

1 reference

12 December 2020

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion

1 reference

12 December 2020

Glucose modulation of insulin and glucagon secretion in nondiabetic and diabetic man.

1 reference

12 December 2020

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

12 December 2020

Occurrence of VIP and peptide HM in human pancreas and their influence on pancreatic endocrine secretion in man

1 reference

12 December 2020

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

1 reference

12 December 2020

Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases

1 reference

12 December 2020

Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction

1 reference

12 December 2020

Sensitivity of insulin secretion to feedback inhibition by hyperinsulinaemia.

1 reference

12 December 2020

Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Redundant parasympathetic and sympathoadrenal mediation of increased glucagon secretion during insulin-induced hypoglycemia in conscious rats

1 reference

12 December 2020

Evidence of a paracrine role for pancreatic somatostatin in vivo

1 reference

12 December 2020

Effects of glucagon-like peptide-I on glucose turnover in rats.

1 reference

12 December 2020

Gastrin-Releasing Peptide: Pharmacokinetics and Effects on Gastro-Entero-Pancreatic Hormones and Gastric Secretion In Normal Men*

1 reference

12 December 2020

Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans

1 reference

12 December 2020

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

1 reference

12 December 2020

Sympathetic nerve stimulation versus pancreatic norepinephrine infusion in the dog: 1). Effects on basal release of insulin and glucagon

1 reference

12 December 2020

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

1 reference

12 December 2020

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

12 December 2020

Somatostatin blockade of acute and chronic stimuli of the endocrine pancreas and the consequences of this blockade on glucose homeostasis

1 reference

12 December 2020

Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women

1 reference

12 December 2020

Stimulation of Glucagon Secretion by Epinephrine in Man

1 reference

12 December 2020

Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.

1 reference

12 December 2020

Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide

1 reference

12 December 2020

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

12 December 2020

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

1 reference

12 December 2020

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

1 reference

12 December 2020

The glucagon-like peptides

1 reference

12 December 2020

Intra-islet insulin permits glucose to directly suppress pancreatic A cell function

1 reference

12 December 2020

The essential role of glucagon in the pathogenesis of diabetes mellitus

1 reference

12 December 2020

Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes.

1 reference

12 December 2020

Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes

1 reference

12 December 2020

Therapeutic strategies based on glucagon-like peptide 1.

1 reference

12 December 2020

Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus

1 reference

12 December 2020

The Inhibitory Effect of Somatostatin on Growth Hormone, Insulin and Glucagon Secretion in Diabetes Mellitus1

1 reference

12 December 2020

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

1 reference

12 December 2020

The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans

1 reference

12 December 2020

Effects of oxytocin upon the endocrine pancreas secretion and glucose turnover in normal man.

1 reference

12 December 2020

Comparison of the suppressive effects of elevated plasma glucose and free fatty acid levels on glucagon secretion in normal and insulin-dependent diabetic subjects. Evidence for selective alpha-cell insensitivity to glucose in diabetes mellitus

1 reference

12 December 2020

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

1 reference

12 December 2020

The vascular order of islet cellular perfusion in the human pancreas

1 reference

12 December 2020

Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes

1 reference

12 December 2020

Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women

1 reference

12 December 2020

GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse

1 reference

12 December 2020

Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

12 December 2020

Exon duplication and divergence in the human preproglucagon gene

1 reference

12 December 2020

The postprandial state: mechanisms of glucose intolerance

1 reference

12 December 2020

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

1 reference

12 December 2020

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

1 reference

12 December 2020

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

12 December 2020

Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study

1 reference

12 December 2020

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

1 reference

12 December 2020

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes

1 reference

12 December 2020

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

1 reference

12 December 2020

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

12 December 2020

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

1 reference

12 December 2020

Glucagonlike peptide-1(7-36)amide suppresses glucagon secretion and decreases cyclic AMP concentration in cultured In-R1-G9 cells

1 reference

12 December 2020

Glucagon-Like Peptide I and Glucose-Dependent Insulinotropic Polypeptide Stimulate Ca2+-Induced Secretion in Rat -Cells by a Protein Kinase A-Mediated Mechanism

1 reference

12 December 2020

Differential effects of glucagon-like peptide-1 (7-36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro

1 reference

12 December 2020

Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic alpha cells.

1 reference

12 December 2020

Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians

1 reference

12 December 2020

The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets

1 reference

12 December 2020

Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide

1 reference

12 December 2020

Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas

1 reference

12 December 2020

Responses of the pancreatic A cell during hypoglycemia and hyperglycemia are dependent on the B cell.

1 reference

12 December 2020

Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas.

1 reference

12 December 2020

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

1 reference

12 December 2020

Studies of pancreatic alpha cell function in normal and diabetic subjects

1 reference

12 December 2020

Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics

1 reference

12 December 2020

Hypoglycemia in diabetes.

1 reference

12 December 2020

GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes

1 reference

12 December 2020

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

1 reference

12 December 2020

Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans

1 reference

12 December 2020

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

1 reference

12 December 2020

Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect.

1 reference

12 December 2020

Suppressive effect of secretin upon pancreatic alpha cell function

1 reference

12 December 2020

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

1 reference

12 December 2020

Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

12 December 2020

Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance.

1 reference

12 December 2020

10.1007/S00125-005-1878-0

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1013989061

0 references

1 reference